Svetlana N. Sharanova

Cladribine in tablets in real clinical practice: Results of treatment of 267 patients with multiple sclerosis in Moscow

Ekaterina Valerievna Popova, V. B. Sosina, Svetlana N. Sharanova, S. N. Zolotova et autres

Introduction. Over the past 30 years, there has been a dramatic change in approaches to the treatment of multiple sclerosis (MS), due to the development of a large number of drugs with different mechanisms of action for the disease-modifying treatment (DMT) of …

ru (code pays fourni par la source)

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara, Achim Berthele et autres

BACKGROUND: Antibodies to the aquaporin-4 (AQP4) water channel in neuromyelitis optica spectrum disorder (NMOSD) are reported to trigger the complement cascade, which is implicated in astrocyte damage and subsequent neuronal injury. The PREVENT study demonstrated that the terminal complement inhibitor eculizumab reduces …

gb, us, jp, de, es, kr, tr, ru, my, tw (code pays fourni par la source)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis

Mikhail Vasilyevich Melnikov, Svetlana N. Sharanova, Anastasiya Sviridova, Vladimir Rogovskii et autres

Glatiramer acetate (GA) is approved for the treatment of multiple sclerosis (MS). However, the mechanism of action of GA in MS is still unclear. In particular, it is not known whether GA can modulate the pro-inflammatory Th17-type immune response in MS. We …

ru (code pays fourni par la source)

Atypical Multiple Sclerosis – Baló’s Concentric Sclerosis: Two Case Reports and a Review

Ekaterina Valerievna Popova, Vasiliy V. Bryukhov, А. Н. Бойко, М. В. Кротенкова et autres

ru (code pays fourni par la source)

A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Glatiramer Acetate 20 mg in Patients with Remitting Multiple Sclerosis: First-Year Study Results

А. Н. Бойко, N. Yu. Lashch, Svetlana N. Sharanova, Mariya N. Zakharova et autres

ru (code pays fourni par la source)

Atypical multiple sclerosis — Balo’s concentric sclerosis: two case-reports and a review

Ekaterina Valerievna Popova, Vasiliy V. Bryukhov, М. В. Кротенкова, O E Konovalova et autres

This article presents two clinical cases of patients diagnosed with Balo's concentric sclerosis. Distinctive features of the pathogenesis in the aspect of differential diagnosis from other forms of multiple sclerosis and possible treatment are discussed.

ru (code pays fourni par la source)

TREATMENT PROBLEMS OF PATIENTS WITH MULTIPLE SCLEROSIS OF CHILDBEARING AGE

Elena V. Popova, Svetlana N. Sharanova

There was a whole series of drugs that change the course of multiple sclerosis over the past 20 years. However, a single algorithm of patients of childbearing age has yet been developed. There are new drugs more efficiently, but at the same …

ru (code pays fourni par la source)

TERIFLUNOMIDE - A NEW TABLETED DRUG FOR THERAPY OF REMITTING DISSEMINATED SCLEROSIS (REVIEW)

Elena V. Popova, M. V. Davydovskaya, S. N. Zolotova, Н. В. Хачанова et autres

This review includes results of experimental and clinical studies of new oral drug teriflunomide for pathogenetic treatment of multiple sclerosis (MS). Given the mechanism of action, clinical data of the studies II and III phases of clinical efficacy, tolerability and safety. Discusses …

ru (code pays fourni par la source)

Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study

N. Yu. Lashch, Svetlana N. Sharanova, Mariya N. Zakharova, O. Trifonova et autres

The article presents the results of international multicenter randomized double-blind, active and placebo-controlled, comparative phase 3 trial. The goal of the study was to demonstrate non-inferiority of BCD-063 (glatiramer acetate, manufactured by JSC «BIOCAD», Russia) to copaxone-Teva (Teva Pharmaceutical Enterprise Co., Ltd., …

ru, us (code pays fourni par la source)

Heavy–light chain interrelations of MS-associated immunoglobulins probed by deep sequencing and rational variation

Yakov A. Lomakin, Maria Yu. Zakharova, Alexey V. Stepanov, Maria A. Dronina et autres

The mechanisms triggering most of autoimmune diseases are still obscure. Autoreactive B cells play a crucial role in the development of such pathologies and, in particular, production of autoantibodies of different specificities. The combination of deep-sequencing technology with functional studies of antibodies …

ru, es, us (code pays fourni par la source)

Efficacy and Tolerance of Glatiramer Acid (Copaxone) on Long-Term Use: 10 Years of Experience at the Moscow City Multiple Sclerosis Center

А. Н. Бойко, M. V. Davydovskaya, T L Demina, N. Yu. Lashch et autres

ru (code pays fourni par la source)

Liposome‐encapsulated peptides protect against experimental allergic encephalitis

Alexey A. Belogurov, Alexey V. Stepanov, Ivan V. Smirnov, Dobroslav Melamed et autres

Multiple sclerosis (MS) is a severe inflammatory and neurodegenerative disease with an autoimmune background. Despite the variety of therapeutics available against MS, the development of novel approaches to its treatment is of high importance in modern pharmaceutics. In this study, experimental autoimmune …

ru, il, gb, fr, Maroc (code pays fourni par la source)